The observation

EviGeno was not born from a business idea. It came from a moment I couldn't walk away from. During my career in the healthcare industry, I encountered patients in the final stages of illness who were still searching — not passively waiting, but actively looking for a trial they might qualify for, a therapy approved somewhere else, a molecule no one had told them about. They hadn't given up. They just didn't know where to look.

What I found on the other side of that search was deeply troubling. The patient advocacy industry, for all its good intentions, is structurally limited — it was never built to conduct deep, individualized medical intelligence research tailored to a single patient's molecular profile and clinical history. And when patients and families try to fill that gap themselves, they often encounter something worse: forums full of unverified claims, wellness products masquerading as treatments, and outright fraudulent services targeting people in desperate circumstances. Too many families reach the end of a serious illness having lost both time and resources on interventions that were never grounded in evidence.

The background

My professional foundation spans clinical genomic testing, regulatory submissions, and medical OSINT — work that gave me a precise, working understanding of how molecular profiles translate into treatment options: which mutations are actionable, which biomarkers open or close trial eligibility, and where the interpretive gaps tend to appear in standard NGS reports.

Alongside that, I developed a practiced capability in medical OSINT — open-source intelligence methodology applied to the healthcare domain. OSINT, in its professional sense, is not about searching Google. It is a structured discipline: knowing which sources exist, how to access and cross-reference them, how to validate information across registries and regulatory filings in multiple languages, and how to synthesize raw intelligence into something a patient and their care team can actually act on.

The name EviGeno reflects this foundation directly: it is a contraction of Evidence and Genomics — a signal that every piece of intelligence we deliver is grounded in the patient's real clinical and molecular reality, not generic information that could apply to anyone.

The practice

EviGeno exists to close the gap between what patients are told is possible and what is actually available — helping people in late-stage illness find treatment options scientifically, rigorously, and matched to their actual individual situation. It operates as an independent research practice with no hospital affiliations, no pharmaceutical partnerships, and no referral arrangements of any kind. Every engagement is driven solely by what the evidence supports for that specific case.

Cases are taken on selectively — only when there is genuine reason to believe the research will add meaningful value. If a case is better served by a different resource, we say so plainly and point in the right direction.

"Every case is treated as the only case. That is not a tagline — it is the only way this kind of research can be done properly."

— Dexter Liu, Founder